Jade Biosciences, Inc.
Jade Biosciences, Inc. (JBIO) Stock Overview
Explore Jade Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
349.6M
P/E Ratio
-0.58
EPS (TTM)
N/A
ROE
2.01%
JBIO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Jade Biosciences, Inc. (JBIO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of N/A.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.58 and a market capitalization of 349.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Tom Frohlich
50
221 Crescent Street Building 23, Waltham
2025